News Sentiment

A sentiment intelligence

Agilent Technologies Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 45 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 134.29 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+2.8% over one week, +3.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Life Science Tools Market Top Players- Agilent Technologies,

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction 2.8% Price confirming higher
Trend fit Trend inactive 3.6% over four weeks
Fair value 5.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 23
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Ad-hoc-news.de 9
TradingView 5
simplywall.st 4
Investing.com 3
Market source 3
Investing.com South Africa 2
Stock Titan 2
MarketWatch 2

Event Lens

What the news is about

Classified themes
Market update 18
Earnings 14
Regulatory and legal 5
Analyst action 3
Macro sensitivity 2
Deals and strategy 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
openPR.com Direct company coverage

Life Science Tools Market Top Players- Agilent Technologies,

The global Life Science Tools Market, valued at USD 183.09 billion in 2025, is projected to reach USD 461.03 billion by 2035, growing at a 9.8% CAGR. This growth is driven by advancements in research technologies, increased investments, and the rising prevalence of chronic diseas

Tone
Positive 65/100
Event
Market update
Published
14 Jul 2026 22:07
Source
openPR.com
Investing.com South Africa Direct company coverage

Agilent receives FDA approval for cancer diagnostic test By Investing.com

Agilent Technologies Inc. received FDA approval for its PD-L1 IHC 28-8 pharmDx assay, a companion diagnostic for specific esophageal and gastric cancers. This test identifies patients eligible for treatment with Bristol Myers Squibb's OPDIVO or OPDIVO QVANTIG. The approval expand

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 17:07
Source
Investing.com South Africa
Investing.com Direct company coverage

Agilent receives FDA approval for cancer diagnostic test

Agilent Technologies Inc. received FDA approval for its PD-L1 IHC 28-8 pharmDx assay, a companion diagnostic for certain esophageal and gastric cancers. This test helps identify patients who may benefit from Bristol Myers Squibb’s OPDIVO treatments. The approval strengthens Agile

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 13:06
Source
Investing.com
Market source Direct company coverage

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

Agilent Technologies Inc. announced FDA approval for its PD-L1 IHC 28-8 pharmDx assay. This companion diagnostic identifies patients with esophageal squamous cell carcinoma, gastric, gastroesophageal junction, and esophageal adenocarcinoma who may be eligible for treatment with B

Tone
Positive 71/100
Event
Regulatory and legal
Published
14 Jul 2026 12:07
Source
Market source
Stock Titan Direct company coverage

FDA-approved Agilent test identifies patients who may be eligible for Opdivo

Agilent Technologies has received FDA approval for its PD-L1 IHC 28-8 pharmDx assay. This diagnostic test identifies patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 12:03
Source
Stock Titan
TradingView Direct company coverage

A6433334 Bond Profile — Key Metrics

This article provides key metrics for the A6433334 bond issued by Agilent Technologies, Inc. The bond has a 4.9% coupon rate and matures on January 15, 2032, with an outstanding amount of $600 million. It also gives a brief overview of Agilent Technologies, Inc., detailing its se

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 11:36
Source
TradingView
TradingView Direct company coverage

A6433334 Bond Risk Profile

This page provides a risk profile for the A6433334 bond from Agilent Technologies, Inc., with a 4.9% coupon rate and maturing on January 15, 2032. It focuses on credit risk assessment by offering key metrics such as security level, inflation protection, and an issuer rating to he

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 11:07
Source
TradingView
Ad Hoc News Direct company coverage

Agilent Technologies stock reflects steady diagnostics demand

Agilent Technologies provides laboratory instruments and diagnostic solutions to various sectors including pharmaceutical, biotechnology, environmental, and clinical laboratories. The company's stock is supported by recurring demand for long-term trends in testing, research, and

Tone
Positive 80/100
Event
Macro sensitivity
Published
13 Jul 2026 22:43
Source
Ad Hoc News
Sahm Direct company coverage

Is Agilent Technologies (A) A Bargain Following Its New Lab Tools And AI Software?

Agilent Technologies (A) has introduced new lab tools and AI-powered software, drawing attention to its stock amidst a gradual improvement in sentiment. While valuation narratives suggest the stock is undervalued, its P/E ratio is higher than its fair ratio despite being lower th

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 20:07
Source
Sahm
TradingView Direct company coverage

Tangible book value per share of Agilent Technologies, Inc. – LSX:929138

This article provides financial information for Agilent Technologies, Inc. (LSX:929138) focusing on its tangible book value per share. The content appears to be a stub or a placeholder from a financial data platform, indicating where this specific financial metric would be displa

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 08:06
Source
TradingView
MSN Direct company coverage

Agilent rises on Q2 beats; adjusts fiscal 2026 guidance

Agilent Technologies reported strong Q2 earnings that surpassed expectations, leading to a rise in its stock. The company also announced adjustments to its fiscal year 2026 guidance. This positive financial performance indicates a robust quarter for Agilent.

Tone
Positive 86/100
Event
Earnings
Published
11 Jul 2026 22:07
Source
MSN
Simply Wall Street Direct company coverage

Does Agilent (A) Signal a Deeper Shift With New AI Biopharma Tools and Columns?

Agilent Technologies has expanded its Altura HPLC column portfolio and introduced the AI-powered xCELLigence RTCA eSight AI module, aiming to enhance data quality, efficiency, and reproducibility in biopharmaceutical research. This move aligns with Agilent's strategy to focus on

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 06:43
Source
Simply Wall Street
TradingView Direct company coverage

Agilent Strengthens Biopharma Growth Prospects With AI Expansion

Agilent Technologies is enhancing its biopharma growth prospects by expanding its AI-enabled laboratory software and automation capabilities, despite recent stock dips. The company launched xCELLigence RTCA eSight AI to simplify live-cell imaging analysis and is integrating AI ac

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 18:07
Source
TradingView
MarketWatch Direct company coverage

Agilent Technologies Inc. stock outperforms competitors on strong trading day

Shares of Agilent Technologies Inc. (A) rose 3.50% on a strong trading day, outperforming the S&P 500 Index (SPX) and the Dow Jones Industrial Average (DJIA). The stock closed at $133.59, 16.65% below its 52-week high. This performance occurred as the broader market also saw gain

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 16:53
Source
MarketWatch
Seeking Alpha Direct company coverage

Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat (NASDAQ:ILMN)

Illumina (ILMN) holds over 90% market share in genomics sequencing with a robust razor-and-blades model, powering a $30B+ market. Following the GRAIL divestment, management is focusing on core sequencing, cost control, and capital return, leading to revenue recovery and margin ex

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 15:10
Source
Seeking Alpha
Ad-hoc-news.de Direct company coverage

Agilent Technologies explores long-term growth drivers as a life sciences leader

Agilent Technologies Inc. is a leading provider of analytical instruments and diagnostic solutions for various industries, including pharmaceuticals and chemicals. The company focuses on high-performance systems like chromatography and mass spectrometry, benefiting from recurring

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 09:43
Source
Ad-hoc-news.de
Investing.com South Africa Direct company coverage

Jefferies resumes Agilent stock coverage with Hold rating By Investing.com

Jefferies has resumed coverage on Agilent Technologies Inc. (NYSE:A) with a Hold rating and a $135 price target, following the company's acquisition of Biocare. The firm expects modest revenue growth and adjusted operating margin accretion from the deal, with slight dilution to e

Tone
Positive 59/100
Event
Deals and strategy
Published
08 Jul 2026 22:36
Source
Investing.com South Africa
Investing.com Direct company coverage

Jefferies resumes Agilent stock coverage with Hold rating

Jefferies has resumed coverage on Agilent Technologies Inc. (NYSE:A) with a Hold rating and a price target of $135, following the company's acquisition of Biocare. The firm anticipates modest revenue growth and improved operating margins from the acquisition, though slight diluti

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 21:51
Source
Investing.com
MarketWatch Direct company coverage

Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors

Agilent Technologies Inc. (A) stock fell 1.58% to $129.07 on Wednesday, underperforming the broader market, as the S&P 500 Index (SPX) dropped 0.28% and the Dow Jones Industrial Average (DJIA) fell 1.09%. The company's stock closed 19.47% below its 52-week high of $160.27.

Tone
Negative 40/100
Event
Market update
Published
08 Jul 2026 16:52
Source
MarketWatch
Insider Monkey Direct company coverage

Is Agilent Technologies, Inc. (A) Stock Positioned for Growth as Life Sciences Sector Trends Stabilize?

Evercore ISI analyst Vijay Kumar recently raised the price target for Agilent Technologies, Inc. (A) to $148, maintaining an Outperform rating, following a review of the MedTech, Life Sciences Tools, and Diagnostics sectors. The positive outlook is supported by stable procedure v

Tone
Positive 72/100
Event
Analyst action
Published
08 Jul 2026 15:06
Source
Insider Monkey
Baystreet.ca Direct company coverage

Agilent Slumps on Expansion Plans

Agilent Technologies Inc. (NYSE: A) shares declined after the company announced an expansion of its Altura HPLC column portfolio, introducing Altura size exclusion chromatography (SEC) and Altura PLRP-S columns. These new columns are designed to support critical analytical workfl

Tone
Negative 29/100
Event
Market update
Published
08 Jul 2026 14:06
Source
Baystreet.ca